EUCTR2012-003331-32-BE进行中（未招募）1 期
A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PRE-TRANSPLANT AND PROMPT POST-TRANSPLANT TREATMENT WITH AZITHROMYCIN TO IMPROVE EARLY ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTATIO
KULeuven and University Hospitals Leuven0 个研究点目标入组 60 人开始时间: 2012年11月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed informed consent
- •- Adult (age at least 18 years old at moment of transplantation)
- •- Single lung transplantation, sequential single (double) lung transplantation or heart-lung transplantation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Known previous allergy for azithromycin (including skin reactions such as rash, urticaria or Stevens-Johnson syndrome, angioneurotic oedema and anaphylaxis)
- •- Retransplantation or multi-organ (other than heart-lung) transplantation
研究者
相似试验
招募中
不适用
A randomized double-blind placebo-controlled trial of Neratinib (HKI-272) after trastuzumab in women with early-stage HER-2/neu overexpressed/amplified breast cancerPER-008-10PUMA BIOTECHNOLOGY INC.,3
进行中（未招募）
1 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITISAtopic dermatitisEUCTR2019-002932-10-LTDermira, a wholly owned subsidiary of Eli Lilly and Company400
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THEPREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERALNEUROPATHY SYMPTOMS WITH PREGABALIN IN SUBJECTS WITH ADVANCED COLORECTAL CANCER - naCHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMSMedDRA version: 8.1Level: LLTClassification code 10029331Term: Neuropathy peripheralEUCTR2006-002917-11-DEPfizer Pharma GmbH200
进行中（未招募）
1 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITISMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic dermatitisEUCTR2019-002932-10-EEDermira, a wholly owned subsidiary of Eli Lilly and Company400
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMS IN SUBJECTS WITH ADVANCED COLORECTAL CANCER - NDEUCTR2006-002917-11-ITPFIZER200